Year All20232022202120202019 Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis Sep 14, 2023 Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results Sep 12, 2023 Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th Sep 06, 2023 Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 Aug 23, 2023 Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia Jul 20, 2023 Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal Jul 17, 2023 Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering Jul 06, 2023 Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration Jul 05, 2023 Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome Jun 15, 2023 Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets May 31, 2023
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis Sep 14, 2023
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th Sep 06, 2023
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 Aug 23, 2023
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia Jul 20, 2023
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal Jul 17, 2023
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration Jul 05, 2023
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome Jun 15, 2023
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets May 31, 2023
